4:48 PM ET
10-Q
Financial Results
Autolus Therapeutics Q3 2026 Results: Net Loss of $55.1M, Loss Narrows
Autolus Therapeutics plc, a foreign private issuer voluntarily filing a Form 10-Q, reported 266,340,330 ordinary shares outstanding as of November 9, 2026. The filing highlights the commercialization of AUCATZYL for adult r/r B-ALL and notes a restructuring and workforce reduction plan initiated in April 2026.
- Key figure
- Net loss $55.1M